Our patients were treated with sorafenib for cytoreduction as it was already part of the AML BFM 2012 trial for children with FLT3-ITD/TKD mutation during induction, consolidation and re-intensification (18). This evidence concerns the gene FLT3 and acute myeloid leukemia.